Reuters logo
BRIEF-Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program
November 6, 2017 / 1:52 PM / a month ago

BRIEF-Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program

Nov 6 (Reuters) - Sarepta Therapeutics Inc

* Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program for the treatment of duchenne muscular dystrophy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below